Physician profile
Catherine Blyth
NPI 1013461763
$1,582.08
in general payments reported to CMS, 2019-2025
28 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.72 · 2022: $226 · 2023: $352 · 2024: $449 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $143.82 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $114.34 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $94.82 | 2023-2025 | Ingrezza |
| Amgen INC. | $91.45 | 2021-2025 | Evenity, Prolia, Prolia |
| Lundbeck LLC | $80.71 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.83 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $62.37 | 2023-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $57.76 | 2023-2024 | |
| Pfizer INC. | $50.87 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $47.84 | 2024-2025 | Nuplazid |
| Astellas Pharma US INC | $46.34 | 2025 | Veozah |
| Exact Sciences Corporation | $45.41 | 2023-2024 | Cologuard Collection Kit |
| Insulet Corporation | $40.92 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $39.57 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.39 | 2024-2025 | |
| Axsome Therapeutics, INC. | $37.19 | 2025 | Auvelity |
| Abbott Laboratories | $35.73 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $31.69 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $30.29 | 2022-2025 | Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $23.66 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $23.22 | 2022 | |
| Radius Health, INC. | $21.34 | 2025 | Tymlos |
| Pharmacosmos Therapeutics INC. | $18.86 | 2023 | Monoferric |
| Dexcom, INC. | $17.03 | 2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $15.43 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.55 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Blyth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.